Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factors associated with time to EGFR TKI treatment in patients with non-squamous metastatic non-small-cell lung cancer.

Future oncology (London, England) - 1 Apr 2022

Marrett Elizabeth, Kwong Winghan Jacqueline, Chow Laura Qm

Abstract excerpt

Aim: Assess factors associated with EGFR TKI initiation among patients with metastatic non-small-cell lung cancer (mNSCLC). Patients & methods: Medicare Part D patients diagnosed with non-squamous mNSCLC and starting an EGFR TKI within 1 year of diagnosis were selected from the Surveillance, Epidemiology and End Results (SEER)-Medicare database. Associations between patient characteristics and time from diagnosis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to United States

Source

Identifiers

PMID: 35147043
DOI: 10.2217/fon-2021-1452

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors associated with time to EGFR TKI treatment in patients with non-squamous metastatic non-small-cell lung cancer.PMID 35147043Read ↗

Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.Semantic proximity Read ↗

Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis.Semantic proximity Read ↗

Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USASemantic proximity Read ↗

Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.Semantic proximity Read ↗

Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.Semantic proximity Read ↗

Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation.Semantic proximity Read ↗

Impact of Molecular Biomarker Test Availability and Timing on Metastatic Non-Small-Cell Lung Cancer Treatment Selection and Clinical Outcomes in the U.S. Medicare PopulationSemantic proximity Read ↗

EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.Semantic proximity Read ↗

Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study.Semantic proximity Read ↗

Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.Semantic proximity Read ↗

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLCSemantic proximity Read ↗

Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.